Tenatoprazole

Tenatoprazole (TU-199) is an orally active imidazopyridine-based proton pump inhibitor with a prolonged plasma half-life. Tenatoprazole inhibits hog gastric H+/K+-ATPase activity with an IC50 of 6.2 μM. Tenatoprazole blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV[1][2][3].

Product Specifications

CAS Number

[113712-98-4]

Product Name Alternative

TU-199

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Proton Pump

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tenatoprazole.html

Purity

99.75

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(C1=NC2=CC=C(OC)N=C2N1)CC3=NC=C(C)C(OC)=C3C

Molecular Formula

C16H18N4O3S

Molecular Weight

346.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Thomson AB, et al. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment Pharmacol Ther. 2006;23 (8) :1179-1187.|[2]Uchiyama K, et al. Effects of TU-199, a novel H+, K (+) -ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats. Methods Find Exp Clin Pharmacol. 1999;21 (2) :115-122.|[3]Mannemuddhu SS, et al. Prazoles Targeting Tsg101 Inhibit Release of Epstein-Barr Virus following Reactivation from Latency. J Virol. 2021;95 (13) :e0246620.|[4]Uchiyama K, et al. The long-lasting effect of TU-199, a novel H+, K (+) -ATPase inhibitor, on gastric acid secretion in dogs. J Pharm Pharmacol. 1999;51 (4) :457-464.